Complix and I-Mab sign deal to develop alphabody cancer therapies

pharmafile | March 11, 2021 | News story | |  Cancer, Complix, oncology 

Biopharmaceutical company Complix has signed a drug discovery deal with I-Mab Biopharma, a clinical-stage company focused on the discovery, development, and commercialisation of novel and highly differentiated biologics in the immuno-oncology therapeutic area.

Under the terms of the agreement, Complix will use its proprietary Alphabody platform to deliver cell-penetrating alphabodies (CPABs) against two immuno-oncology intracellular targets. The resulting CPABs will undergo clinical development that will be jointly managed by both companies.

CPABs are a revolutionary class of small proteins engineered to bind to a variety of antigens. Available data show that CPABs have the potential to address a wide range of disease targets, particularly intracellular targets that are difficult for current therapies to reach.

In addition to crossing cellular membranes, alphabodies have the potential both to cross the blood-brain barrier to address CNS diseases, and to be delivered orally given their ability to cross the gut wall.

I-Mab will have an exclusive licence to commercialise the CPABs in Greater China, with commercial rights for the rest of the world being equally owned by both companies. In return, Complix is entitled to receive an upfront payment and potential development milestones fees, as well as tiered royalties.

Mark Vaeck, CEO of Complix, said: “We are pleased to have signed this important new oncology/immuno-oncology collaboration with I-Mab, based on the unique capabilities of our CPABs to address intractable intracellular targets. We are looking forward to developing novel CPAB drug candidates that have a beneficial therapeutic impact on the two immuno-oncology targets put forward by I-Mab.

“We are also happy to be working with a partner with the ability and commitment to commercialising these products in Greater China and to have retained a commercial interest in these CPABs in the rest of the world, providing us with an additional opportunity to generate shareholder value.”

Taylor Guo, Chief Scientific Officer of I-Mab, added: “The partnership with Complix is part of our strategy to create a new cycle of pipeline programmes, as our current set of assets advances rapidly towards late-stage clinical development and Biologics Licence Application. As a company pushing the boundaries on innovation, I-Mab is anchoring its efforts in new medicines that have transformative potential.

“We have been impressed with the data that Complix has generated to support the unique ability of its CPAB platform to address intracellular targets, and we believe that these CPABs are pioneering the next wave of cancer therapeutics that can potentially address the unmet needs in patient and clinical care.”

Darcy Jimenez

Related Content


BioInvent and Transgene announce positive phase 1a solid tumour trial data

Sweden-based BioInvent and French Transgene, both biotech companies, have reported positive phase 1a data from …


AstraZeneca shares oncology data at ASCO 2023

AstraZeneca plans to share data from its oncology pipeline at the American Society of Clinical …

FDA announces acceptance and priority review of NDA for LUMISIGHT imagining agent for breast cancer

Lumicell has announced that the US Food and Drug Administration (FDA) has accepted and granted …

Latest content